On 13 May 2026, Hong Kong's Medical Device Division (MDD) updated Guidance Notes GN-00 — the foundational definitions document for the Medical Device Administrative Control System (MDACS) — to formally include injectable dermal fillers and mucous membrane fillers as medical devices. The change was effective immediately and carries real consequences for anyone receiving filler injections in Hong Kong.
This is not a general cosmetics regulation or a skincare registration rule. It is a targeted classification decision that puts hyaluronic acid fillers, calcium hydroxylapatite products, and other injectable volumising agents under the same device oversight framework that governs surgical implants, diagnostic instruments, and cardiac equipment. If you are getting filler in Hong Kong — or considering it — this changes what you should ask your clinic.
What actually changed
The GN-00 update, issued as GN-00:2026-1(E), made three specific revisions:
Clause 2.38 was revised. This clause defines what qualifies as a medical device under MDACS. The updated definition now explicitly encompasses injectable products that modify, replace, or support anatomical structures — the functional language that captures dermal fillers.
Appendix 1 was added. This new appendix lists "injectable dermal fillers or mucous membrane fillers" as items specified for the purpose of Clause 2.38(b). This is the operational mechanism: a specific product category appended to the device definition, removing prior ambiguity about whether fillers qualify.
Document formatting was updated. This is administrative only.
Before this update, dermal fillers in Hong Kong existed in a regulatory grey area. Injectable products were generally classified as pharmaceutical products under the Pharmacy and Poisons Ordinance (Cap. 138). But many filler products — especially those marketed purely for cosmetic use — did not fit neatly into either the pharmaceutical framework or the device framework. They were too "device-like" to register as drugs but not explicitly named as medical devices. The result: many dermal filler products on the Hong Kong market operated without clear regulatory classification, and the MDD could reject listing applications from filler manufacturers who could not demonstrate a recognised medical indication.
The GN-00 update resolves that ambiguity. Injectable dermal fillers are now expressly medical devices under MDACS, regardless of whether the intended use is cosmetic, reconstructive, or functional.
What MDACS classification means in practice
MDACS is a risk-based regulatory framework adapted from the Global Harmonization Task Force (GHTF) model. It classifies medical devices into four risk tiers: Class I (low risk), Class II (low-to-moderate), Class III (moderate-to-high), and Class IV (high risk). Injectable dermal fillers — substances introduced into the body that remain in tissue for weeks to months — will typically fall into Class II or Class III, depending on the specific product, its duration in the body, and whether it incorporates additional materials like lidocaine.
Under MDACS, listing a medical device requires:
A Local Responsible Person (LRP). This is a Hong Kong-registered entity that serves as the regulatory liaison between the manufacturer and the MDD. The LRP handles the listing application, maintains supply records, manages adverse event reporting, and coordinates any product recalls. If a filler brand has no LRP in Hong Kong, it has no MDACS listing pathway.
ISO 13485 certification. The manufacturer must hold certification under ISO 13485, the international quality management standard for medical devices. This is not optional. It covers design controls, production processes, traceability, and post-market surveillance.
Technical documentation. A Summary Technical Document (STED) must demonstrate that the device meets the Essential Principles of Safety and Performance, including biocompatibility data, sterilisation validation, and clinical evidence of safety and effectiveness.
Reference country approvals. The MDD's Expedited Approval Scheme allows manufacturers to leverage existing regulatory approvals from recognised reference countries — such as the U.S. FDA, EU CE marking, or Health Canada — to support the Hong Kong listing application. Products without reference country approvals face a longer, more involved review.
Currently, MDACS listing is voluntary — there is no legal requirement for a medical device to be listed before it is sold in Hong Kong. But that distinction is narrowing. Since March 23, 2026, Stage C of the Department of Health's procurement rules requires all applicable medical devices to hold a valid MDACS listing certificate for government tenders. The government has also announced plans to establish the Centre for Medical Products Regulation (CMPR) by the end of 2026, with legislation for mandatory statutory medical device regulation expected to follow.
For dermal fillers specifically, the GN-00 update means that manufacturers who previously could not list their products due to the cosmetic-only classification barrier can now apply for MDACS listing through the device pathway. Products previously rejected may now qualify.
There is also a real cost signal behind that listing decision. Public registration-service pricing is usually opaque, which is why Pure Global's online pricing is useful as a market benchmark: its Hong Kong Local Responsible Person package starts at US$2,000 per year for one Class I/II medical-device listing and US$3,000 per year for one Class III/IV listing, excluding government or third-party fees. For a filler brand, that is not the whole cost of compliance, but it shows that MDACS listing requires an actual local regulatory budget, not just a marketing claim.
Why this matters for patients
Product traceability
When a filler product is listed under MDACS, it enters a tracked system. The LRP must maintain records of every unit supplied in Hong Kong — lot numbers, quantities, distribution channels. If an adverse event occurs, the MDD can trace the specific lot, identify other patients who received product from the same batch, and coordinate a recall if necessary.
Without MDACS listing, none of this infrastructure exists for that product. A filler brand operating outside the MDACS framework has no mandatory adverse event reporting obligation in Hong Kong, no traceability requirements, and no structured recall mechanism.
Adverse event reporting
MDACS-listed devices are subject to the adverse event reporting requirements in Guidance Notes GN-03. Any event involving a listed medical device that results in death, serious injury, or could have led to death or serious injury if it recurred must be reported by the LRP to the MDD. This includes vascular occlusion, tissue necrosis, blindness, severe allergic reactions, and infections linked to the device.
This reporting requirement creates accountability. When a filler is listed, the manufacturer and their LRP have a legal obligation to report serious complications to the Hong Kong health authority. When a filler is not listed, complications may go unreported — not because they do not happen, but because there is no mechanism requiring anyone to document them.
The credibility signal
MDACS listing does not guarantee that a product is safe or effective. The FDA's 510(k) clearance pathway for dermal fillers has its own limitations, and regulatory listing anywhere is a floor, not a ceiling. But in Hong Kong's current environment — where aesthetic medicine is not recognised as a medical specialty, where general practitioners can perform filler injections without additional training, and where the Consumer Council found that 90% of patients receiving high-risk aesthetic treatments were treated by beauticians rather than doctors — a filler product that has gone through MDACS listing at least demonstrates that the manufacturer has invested in quality management, technical documentation, and a local regulatory presence.
The inverse is also informative: if a filler brand available in Hong Kong has no MDACS listing, no LRP, and no ISO 13485 certification, the question is what quality controls govern that product's manufacturing, storage, and distribution — and what happens when something goes wrong.
The context behind the change
Hong Kong's aesthetic medicine industry has a documented history of regulatory gaps with real patient consequences:
A 2012 incident at the DR Beauty Chain involved a blood transfusion procedure administered in a beauty-service setting that caused disseminated mycobacterial infections. The incident prompted the formation of the Working Group on Differentiation between Medical Procedures and Beauty Services.
In 2025, the South China Morning Post reported on patients who developed hard lumps from filler injections performed at well-known medical beauty chains, with clinics denying responsibility and patients unable to find specialists willing to perform corrective surgery.
The Hong Kong Consumer Council has repeatedly called for specific legislation governing medical beauty services, noting that the existing framework does not adequately define the boundary between medical procedures and beauty services.
A 2023 study published in the Journal of Plastic, Reconstructive & Aesthetic Surgery found that in the UK — which faces similar regulatory gaps — 68% of cosmetic practitioners administering injections were not medical doctors. Hong Kong's regulatory environment is at least as permissive.
The GN-00 update is a targeted regulatory response to a specific classification gap. It does not address the broader issues of practitioner qualification, clinic licensing, or consent standards in Hong Kong's aesthetic industry. Those remain unresolved.
What to ask your Hong Kong clinic
If you are considering dermal filler treatment in Hong Kong, the GN-00 update gives you a new framework for evaluating both the product and the clinic:
Ask which filler product will be used, and whether it is listed under MDACS. The MDD maintains a publicly accessible List of Medical Devices on its website. If the product is listed, it has gone through the MDACS review process. If it is not, ask why.
Ask who manufactures the filler and whether they hold ISO 13485 certification. This is a baseline quality management standard for medical device manufacturing. A manufacturer that does not hold it is producing filler outside the quality framework that governs listed medical devices globally.
Ask whether the clinic stocks hyaluronidase. This enzyme dissolves hyaluronic acid filler and is the emergency treatment for vascular occlusion — the most time-sensitive complication in aesthetic injectables. Any clinic that injects HA filler without hyaluronidase on site cannot manage its most dangerous complication.
Ask who is performing the injection. Hong Kong's Medical Registration Ordinance (Cap. 161) prohibits unregistered persons from practising medicine. However, the boundary between "medical treatment" and "beauty service" has been contested, and the enforcement record is inconsistent. Board-certified dermatologists and plastic surgeons have the deepest training in facial vascular anatomy and complication management. General practitioners can legally inject but may have minimal specific training in aesthetic injection technique.
Ask for the lot number. Every MDACS-listed filler product carries a lot number on its packaging. Document it. If an adverse event occurs, the lot number enables the MDD to trace the product through the supply chain. If the clinic will not provide a lot number, that is a warning signal about their documentation practices.
Ask for documentation. Record the product name, lot number, injection sites, volume per site, date, and the injector's credentials. If you need follow-up care — in Hong Kong or elsewhere — this documentation allows the next provider to understand what was placed and where.
How this fits into the global regulatory picture
Hong Kong's classification of dermal fillers as medical devices aligns the territory with most major regulatory jurisdictions:
United States: The FDA classifies dermal fillers as medical devices and requires 510(k) premarket notification or PMA approval. The FDA maintains a publicly accessible database of approved dermal fillers with product-specific safety information.
European Union: Under the EU Medical Device Regulation (MDR 2017/745), dermal fillers — both absorbable and non-absorbable — are classified as Class III medical devices, the highest risk tier for non-active implantable devices. This requires notified body involvement, clinical evaluation, and post-market surveillance.
Mainland China: Dermal fillers are regulated as medical devices under the National Medical Products Administration (NMPA). Hyaluronic acid fillers are typically classified as Class III medical devices requiring registration.
South Korea: Dermal fillers are regulated as medical devices under the Ministry of Food and Drug Safety (MFDS), generally classified as Class III or Class IV.
Hong Kong's GN-00 update brings the territory's classification of dermal fillers into alignment with these jurisdictions — closing a gap that had left fillers in regulatory limbo for years.
Sources
- Hong Kong Medical Device Division. "The Guidance Notes '[GN-00] Guidance Notes for Definitions and Abbreviations for Medical Device Administrative Control System' has been updated." 13 May 2026. https://www.mdd.gov.hk/en/whats-new/mdacs-activities/index-id-2363.html
- Hong Kong Medical Device Division. GN-00:2026-1(E): Definitions and Abbreviations for the Medical Device Administrative Control System. https://www.mdd.gov.hk/filemanager/common/mdacs/GN-00-E.pdf
- Cisema. "Hong Kong Expands Medical Device Listing Scope for Injectable Dermal Fillers." 28 May 2026. https://cisema.com/news/hong-kong-dermal-fillers-update
- Asia Actual. "Hong Kong Adds Dermal Fillers Under Medical Device Definition." 14 May 2026. https://asiaactual.com/blog/hong-kong-updates-mdacs-definition-of-medical-device
- Pure Global. "Simple, Transparent Pricing for Global Medical Device Registration." https://www.pureglobal.com/services/pricing
- Hong Kong Consumer Council. Report on medical beauty services. As cited in South China Morning Post, "More legislation needed to regulate Hong Kong's medical beauty service industry, says watchdog." https://www.scmp.com/news/hong-kong/health-environment/article/2053883/more-legislation-needed-regulate-hong-kongs
- Wong DSY. "Regulation of the beauty industry." Hong Kong Medical Journal. Vol 18, No 6, December 2012. https://www.hkmj.org/system/files/hkm1212p542.pdf
- Hong Kong Department of Health. Report of the Working Group on Differentiation between Medical Procedures and Beauty Services. 2013. https://www.dh.gov.hk/english/useful/useful_medical_beauty/files/WG_report_eng.pdf
- U.S. Food and Drug Administration. "Dermal Fillers (Soft Tissue Fillers)." https://www.fda.gov/medical-devices/aesthetic-cosmetic-devices/dermal-fillers-soft-tissue-fillers
- CMS Law. "Hong Kong Centre for Medical Products Regulation to be established by the end of 2026." https://cms.law/en/hkg/legal-updates/hong-kong-centre-for-medical-products-regulation-to-be-established-by-the-end-of-2026
